First Patient Enrolled in DEEPER CHALLENGE Trial of Reflow Spur in Select CLTI Cohort

July 2, 2026—Reflow Medical, Inc. announced the enrollment of the first patient in the DEEPER CHALLENGE clinical trial, which is investigating early vessel recoil after below-the-knee treatment using the company’s Spur peripheral retrievable scaffold system in combination with a commercially available drug-coated balloon.

StarMed America Receives FDA Clearance for RFA Devices to Treat Thyroid Nodules

July 2, 2026—StarMed America announced FDA 510(k) clearance for its radiofrequency ablation (RFA) devices for the treatment of thyroid nodules.

Penumbra’s Red 72 Silver Label Reperfusion Catheters Receive CE Mark Approval for Acute Ischemic Stroke

June 30, 2026—Penumbra Inc. announced it has received CE Mark approval for its Red 72 Silver Label and Red 72 Silver Label with SendIt technology.

FIH AAA Study of Nectero EAST System Evaluates 2-Year Proximal Neck Dynamics

June 30, 2026—Nectero Therapeutics announced the 2-year findings from a first-in-human (FIH) multicenter study evaluating treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using the company’s investigational Nectero endovascular aneurysm stabilization treatment (EAST) system.

GE’s Allia Upgrade Pathways Introduced for Existing Interventional Suites

June 30, 2026—GE HealthCare announced the introduction of Allia platform upgrade pathways that are designed to help customers modernize select legacy Innova and Discovery image guiding solutions (IGS) systems.

Artivion’s AMDS Hybrid Prosthesis Approved by FDA

June 30, 2026—Artivion, Inc. announced that the FDA has approved the company’s AMDS hybrid prosthesis, an aortic arch remodeling device for use in the treatment of acute DeBakey type I aortic dissections with either clinical or radiographic malperfusion.

SKYWARD Pivotal Studies of Shockwave SkyRunner Carotid IVL Platform Begin Enrollment

June 25, 2026—Johnson & Johnson announced the initiation of its SKYWARD investigational device exemption (IDE) clinical program evaluating the company’s Shockwave SkyRunner carotid intravascular lithotripsy (IVL) system for the treatment of calcified carotid arteries when used before stenting with a commercially available transcarotid or transfemoral stent system.

STRIDE Pivotal Trial of CereVasc’s eShunt System Completes Enrollment

June 24, 2026—CereVasc, Inc. announced it has completed patient enrollment in the STRIDE pivotal trial, which is evaluating the company’s investigational eShunt system in patients with normal pressure hydrocephalus (NPH).